Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.38 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.38 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.32 |
| ▸ | NPC1 | O15118 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.30 |
| ▸ | PMM2 | O15305 | 1/20 | 0.30 |
| ▸ | MPI | P34949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10818196 | 0.80 | TXNRD1 (0.38) | TXNRD1TXNRD3TXNRD2MAPTALDH1A1 | |
| SCHEMBL10818074 | 0.80 | MAPT (0.44) | TXNRD1TXNRD3TXNRD2MAPTALDH1A1 | |
| SCHEMBL17008917 | 0.80 | MAOA (0.32) | ALDH1A1PTGER4TYMSPMM2MPI | |
| SCHEMBL17008811 | 0.74 | PTGER4 (0.31) | PTGER4 | |
| SCHEMBL2251607 | 0.71 | MAPT (0.41) | TXNRD1TXNRD3TXNRD2MAPTALDH1A1 | |
| SCHEMBL3469093 | 0.71 | ALDH1A1 (0.44) | ALDH1A1LMNAPTGER4TYMSPMM2 | |
| SCHEMBL30949613 | 0.71 | HTR2A (0.43) | MAPTMTNR1BMEN1LMNAKMT2A | |
| SCHEMBL20741822 | 0.71 | HTR2A (0.43) | MAPTMTNR1BMEN1LMNAKMT2A | |
| SCHEMBL10815482 | 0.70 | MAPT (0.47) | TXNRD1TXNRD3TXNRD2MAPTALDH1A1 | |
| SCHEMBL27031692 | 0.70 | TXNRD1 (0.38) | TXNRD1TXNRD3TXNRD2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2443092-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | Pfizer Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
| WO-2010146488-A1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | TXNRD1 699/4885TXNRD3 615/4885TXNRD2 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.